TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Real World Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male patients diagnosed with moderate to severe hemophilia A (≤ 5% FVIII:C (Factor VIII Coagulant activity))~* Any age~* ≥ 50 exposure days (EDs) to any FVIII product~* Patients with or without history of inhibitors~  * Patient with previous history of inhibitors, with at least 2 consecutive negative inhibitor tests and on standard prophylaxis therapy for at least 1 year prior to study entry~ * No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor~    * Evidence of FVIII inhibitor as measured by the Nijmegen-modified Bethesda assay \[\<0.6 Bethesda units (BU/mL)\] or Bethesda assay \[\< 1.0 BU/mL\] in 2 on consecutives samples~   * Documented or clinical suspicion of shortened FVIII half-life (\< 6 hrs)~* Currently on or plan to start prophylaxis therapy with KOVALTRY~* Written informed consent~Exclusion Criteria:~* Patients participating in an investigational program with interventions outside of routine clinical practice~* Patients with an additional diagnosis of any bleeding/coagulation disorder other than hemophilia A~* Patients on Immune Tolerance Induction (ITI) treatment at the time of enrollment

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY81-8973 (Type: None): Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged at least 18 years.~* Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic.~* Radiological documentation of disease progression while on a previous continuous treatment with an first or second generation of EGFR TKI e.g. gefitinib or erlotinib.~* patients must also have confirmation of tumour T790M mutation status (confirmed positive) after disease progression on the prior EGFR TKI.~* Eastern cooperative oncology group performance status (ECOG PS) of 0-1.~* a minimum life expectancy of 12 weeks.~* At least one lesion, not previously irradiated during the study screening period, that can be accurately measured at baseline according to RECIST 1.1.~* Agree to use routine adequate and effective contraceptive measures during the entire study period and within 6 weeks after the last dose pre-menopausal fertility possible; Female patients need to exclude pregnancy (ie negative pregnancy test) and in non-lactation period.~Exclusion Criteria:~* Treatment with a first or second generation of EGFR-TKI within 10 days of study entry; previous treatment with a third generation of EGFR-TKI.~* Unresolved toxicities from prior therapy.~* Unstable spinal cord compression/brain metastases.~* Severe/uncontrolled systemic diseases, including uncontrolled hypertension, bleeding diatheses or infection.~* QTcF≥470 msec（female）or QTcF≥450 msec（male）during the screening period.~* Severe respiratory diseases such as interstitial lung disease, severe asthma, pulmonary embolism, etc.~* previous treatment with 2 or more lines of Chemotherapy or immunotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- D-0316 (Type: EXPERIMENTAL): Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Healthy subject in good health, as determined by a medical history, physical examination including vital signs and clinical laboratory tests:~* with a body weight between 45 kg and 95 kg if male, between 40 kg and 85 kg if female, and with a Body Mass Index (BMI) between 18 and 30 kg/m²~* classified into one of the 4 groups of metabolizers according to his/her CYP2C19 genotype:~  * Ultrarapid Metabolizers (UMs, CYP2C19\*1/\*17 and CYP2C19\*17/\*17)~ * homozygous Extensive Metabolizers (homoEMs, CYP2C19\*1/\*1)~ * heterozygous Extensive Metabolizers (heteroEMs, CYP2C19\*1/\*2 and CYP2C19\*1/\*3)~ * Poor Metabolizers (PMs, CYP2C19\*2/\*2 and CYP2C19\*2/\*3)~Exclusion criteria:~* Evidence of inherited disorder of coagulation/hemostasis functions~* Subject smoking more than 10 cigarettes or equivalent per day~* Unability to abstain from intake of any drug affecting hemostasis throughout the whole study duration~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Sequence clopidogrel 300/75 mg - 600/150 mg (Type: EXPERIMENTAL): Period 1:~* Day 1: clopidogrel, 300 mg loading dose + placebo~* Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Period 2:~* Day 1: clopidogrel, 600 mg loading dose~* Day 2 to Day 5: clopidogrel, 150 mg, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours
- Sequence clopidogrel 600/150 mg - 300/75 mg (Type: EXPERIMENTAL): Period 1:~* Day 1: clopidogrel, 600 mg loading dose~* Day 2 to Day 5: clopidogrel, 150 mg, once daily~Period 2:~* Day 1: clopidogrel, 300 mg loading dose + placebo~* Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin E on Staple Line and Anastomoses of Roux-en-Y Gastric Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI \>40 Kg/m2 or \>35 Kg/m2 associated to obesity-related comorbidities~* Patients undergoing Roux-en-Y gastric bypass as bariatric procedure~* Patients accepting to participate in the study and signing and Informed Consent form~Exclusion Criteria:~* Patients undergoing other bariatric techniques~* Patients undergoing Roux-en-Y gastric bypass as revisional procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin E acetate (Type: EXPERIMENTAL): Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
- Control group (Type: SHAM_COMPARATOR): No ointment will be applied

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed gastric cancer~* Clinical stage : - Borrmann type IV~  * Large Borrmann type III (\>8cm)~ * Locally extensive nodal disease~* No evidence of metastasis~* Patients with tumor lesions which can be easily obtained fresh tumor tissue through repeated biopsies.~* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.~* Age≥ 20 years old.~* Performance status of Eastern Cooperative Oncology Group 0 to 2.~* Adequate organ function.~Exclusion Criteria:~1. metastatic disease~2. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.~3. Subjects with an uncontrolled major cardiovascular disease (including AMI within 12 months, unstable angina within 6 months, over NYHA class III congestive heart failure, congenital long QT syndrome, 2° or more AV Block and uncontrolled hypertension)~4. Pregnant or lactating female~5. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction DCS chemotherapy (Type: EXPERIMENTAL): 1. Induction chemotherapy -- S-1 35mg/m2 bid day 1-14~   * Docetaxel 30 mg/m2 day1, 8~  * Cisplatin 30 mg/m2 day1, 8~2. Chemoradiotherapy : S-1 20 mg/m2 bid (Day 1-14, 21-28) cisplatin (30 mg/m2/day, Day 1,8, 21,28), Radiotherapy 45 Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants between 18 and 55 years of age, in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity are required for entry into the study.~* Participants will be required to have at least four teeth with facial/cervical erosion, abrasion and/or gingival recession which respond to qualifying evaporative (air) assessment at the Screening visit and have at least two teeth (incisors, canines or pre-molars) demonstrating signs of sensitivity, measured by qualifying tactile threshold (Yeaple ≤ 20 gram (g)) and evaporative (air) (Schiff Sensitivity Score ≥ 2) assessments at the Baseline visit.~Exclusion Criteria:~* Specific Dentition Exclusions for Test teeth~  1. Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of Screening.~ 2. Tooth with exposed dentin but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing etiologies other than erosion, abrasion or recession of exposed dentin.~ 3. Sensitive tooth not expected to respond to treatment with an over-the-counter dentifrice in the opinion of the investigator~* Use of a sensitivity dentifrice within 8 weeks of screening~* Individuals who require antibiotic prophylaxis for dental procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 5% calcium sodium phosphosilicate/ sodium monofluorophosphate (Type: EXPERIMENTAL): Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
- 0% calcium sodium phosphosilicate/sodium monofluorophosphate (Type: ACTIVE_COMPARATOR): Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
- Sodium monofluorophosphate (Type: ACTIVE_COMPARATOR): Dentifrice containing 1000 ppmF as sodium monofluorophosphate
- Sodium fluoride (Type: ACTIVE_COMPARATOR): Dentifrice containing 1100 ppmF as sodium fluoride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* coronary artery disease~* elective surgery, planned coronary artery bypass graft~* moderate hypothermia or normothermia~* cardiac arrest cold and warm cardioplegia~* normal of moderately impaired left ventricular systolic function~* written informed consent~Exclusion Criteria:~* pregnancy or child bearing potential~* ongoing treatment with nicorandil or sulfonylurea medication~* severe renal or hepatic dysfunction~* ongoing myocardial infarction or unstable angina

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xenon (Type: EXPERIMENTAL): None
- Sevoflurane (Type: ACTIVE_COMPARATOR): None
- Total intravenous anaesthesia (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Optimal Heart Failure Therapy in accordance with European and National Guidelines~* LVEF ≤ 0.40~* eGFR \> 30 ml/min/1.73 m2~* BMI \< 45 kg/m2~* NYHA class I-III~* Age \> 18 years~* If T2D - optimal treatment in accordance with European and National Guidelines~* If T2D - stable doses of antiglycemic treatment for 30 days~* If T2D - HbA1C 6.5-10%~Exclusion Criteria:~* CRT-D/-P implanted \< 90 days~* Uncorrected severe valvular disease~* Non-compliance~* Use of metalozone~* NYHA IV~* Age \> 85 years~* Dementia~* Admission for HF \< 30 days~* Admission for hypoglycemia \< 12 month~* Known sustained VT~* Symptomatic hypotension and systolic BP \< 95 mmHg~* Unable to perform an exercise test~* Immobilization~* Pregnancy~* Participation in other medical trials~* Previous intolerance of Empagliflozin or excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin 10 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of AT-527 in Healthy and HCV-Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All subjects (healthy and HCV-infected subjects):~* Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug~* Must have a negative pregnancy test at Screening and prior to dosing~* Minimum body weight of 50 kg~* Willing to comply with the study requirements and to provide written informed consent~Additional inclusion criteria for HCV-infected subjects:~* Must have not received prior treatment for HCV infection~* Documented clinical history compatible with chronic HCV infection~* Plasma HCV RNA ≥ 5.0 log10 IU/mL at Screening.~Exclusion Criteria:~All subjects (healthy and HCV-infected subjects):~* Pregnant or breastfeeding~* Infected with hepatitis B virus or HIV~* Abuse of alcohol or drugs~* Use of other investigational drugs within 28 days of dosing~* Other clinically significant medical conditions or laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AT-527 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Academic Stress and Proinflammatory Cytokines: Omega-3 Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* OSU preclinical medical or dental student, or graduate nursing student~* male or female~Exclusion Criteria:~* taking certain medications with immune or endocrine effects~* chronic health conditions~* smoking~* excessive use of alcohol or caffeine~* significant digestive problems~* routine use of fish oil or flaxseed supplements or high fish intake~* fish allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): Placebo oral Omega-3 fish oil supplementation
- 1 (Type: EXPERIMENTAL): oral Omega-3 fish oil supplementation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Body weight of at least 25 pounds~* diagnosis of Lennox-Gastaut syndrome and an electroencephalogram (EEG) with an abnormal pulsation pattern~* atypical absence seizures and drop attacks (i.e., tonic-atonic seizures) among other seizure types that could include tonic-clonic, myoclonic, and minor-motor~* at least 60 seizures during the month before baseline~* must be maintained on 1 or 2 antiepileptic drugs~* females must not have had their first menstrual period, or are physically incapable of child bearing, or if of child bearing potential, sexually abstinent, or using adequate contraceptive measures, and have a negative pregnancy test before study entry.~Exclusion Criteria:~* Patients whose seizures are due to a progressive disease (for example, active infection, cancer or metabolic disturbance)~* have a significant recent history (within 2 years) of medical diseases (respiratory, heart, gastrointestinal, blood diseases, rheumatic fever or cancer)~* history of alcohol or drug abuse.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 30 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria: Male or female who participated in Undeca-Pn-010 study, were part of the blood subset and received 4 doses of GSK Biologicals' 11Pn-PD vaccine, or Havrix vaccine. Exclusion criteria: Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceeding the first dose of study vaccine, or planned use during the study period. Administration of any additional pneumococcal vaccine since study end of Undeca-Pn-010 (347414/010)

- Gender: ALL
- Minimum Age: 31 Months
- Maximum Age: 57 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Singleton infants born at 25-32 weeks gestation who are \< 38 weeks post-conceptual age at enrollment~2. First infant of twin gestation born at 25-32 weeks gestation who requires a blood transfusion; if both infants require transfusion on the same day the larger infant will be enrolled.~3. Receiving bolus enteral feeds \[PO (bottle) and/or PE (feeding tube)\] of at least 60 cc/kg/day~4. A planned packed red blood cell transfusion, as per the clinical team, for anemia~5. Infant is very likely to require a blood transfusion according to the attending neonatologist.~Exclusion Criteria:~1. Known congenital anomalies of the heart, brain, kidneys or intestine~2. Chromosomal abnormality~3. Intrauterine growth restriction at \< 3% for weight at birth since this has been shown to alter mesenteric BFV and the post-prandial hyperemia~4. Twin to twin transfusion sequence~5. Higher order multiples~6. Patent ductus arteriosus known to be present or currently being treated~7. History of definite necrotizing enterocolitis Bell Stage 2 or greater~8. Concurrent treatments with antibiotics or steroids~9. Feeding intolerance, defined as gastric aspirate \> 30% of feed volume on 3 sequential feeds~10. Concurrent enrollment in another randomized trial~11. Infants discharged or transferred to another facility without having received a PRBC transfusion will be excluded post-hoc.

- Gender: ALL
- Minimum Age: 25 Weeks
- Maximum Age: 38 Weeks
- Healthy Volunteers: f

Study Arms:
- group 1 (Type: NO_INTERVENTION): All babies \<1250 gm at the time of the study are enrolled into this arm, and randomized to be NPO during the PRBC transfusion
- group 2 (Type: ACTIVE_COMPARATOR): Babies \<1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
- group 3 (Type: NO_INTERVENTION): All babies \>1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
- group 4 (Type: EXPERIMENTAL): All babies \<1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete